EICHOR
● Active Not Recruiting
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Condition: Non-small Cell Lung Cancer (NSCLC) · Sponsor: Merck Sharp & Dohme LLC
About this study
The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs). The primary hypotheses of this study is that sacituzumab tirumotecan is better than platinum-based doublet chemotherapy (pemetrexed and carboplatin) in regard to overall survival (OS).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (156)
| Kaiser Permanente - Oakland ( Site 0054) | Oakland, California, United States | — |
| Kaiser Permanente - Roseville ( Site 0055) | Roseville, California, United States | — |
| Kaiser Permanente - San Francisco ( Site 0056) | San Francisco, California, United States | — |
| Kaiser Permanente - Santa Clara ( Site 0057) | Santa Clara, California, United States | — |
| Kaiser Permanente-Kaiser Permanente ( Site 0036) | Vallejo, California, United States | — |
| Kaiser Permanente - Walnut Creek ( Site 0058) | Walnut Creek, California, United States | — |
| Mid Florida Hematology and Oncology Center ( Site 0005) | Orange City, Florida, United States | — |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0003) | Marietta, Georgia, United States | — |
| University of Michigan ( Site 0009) | Ann Arbor, Michigan, United States | — |
| Cox Medical Center North - Cox Medical Center/ Hematology/Medical Oncology ( Site 0051) | Springfield, Missouri, United States | — |
| Astera Cancer Care ( Site 0032) | East Brunswick, New Jersey, United States | — |
| Stony Brook University-Cancer Center ( Site 0038) | Stony Brook, New York, United States | — |
+ 144 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06305754